Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Gaining Momentum in the Treatment of Eye Disease

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.

Read More

Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock

January 8, 2015

MENLO PARK, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced the pricing of its public offering of 2,399,457 shares of its common stock at a public offering price of $59.00 per share, before underwriting discounts, commissions and estimated expenses.

Read More

Read All Avalanche News